Reva Medical Announces First Implant of Fantom in Turkey

REVA Medical, Inc. a leader in bioresorbable polymer technologies for vascular applications, announced today launch of the Fantom bioresorbable scaffold in Turkey with implants conducted during the first week of introduction at three separate hospitals. The procedures were conducted in Istanbul and Antalya by Prof. Bilal Boztosun, Chief of Cardiology at the Mega Medipol University Hospital, Prof. Ömer Göktekin, Chief of Cardiology at the Memorial B. Evler Hospital, and Prof. Ismail Ates, Chief of Cardiology at the Medical Park Hospital.

Turkey is an important market for bioresorbable scaffolds. It is a large country with a population that is similar to Germany and has approximately 100 hospitals performing cardiac catheterizations in Istanbul alone. REVA previously announced a commercial distribution partnership with Kardionet HealthCare and Foreign Trading, Ltd (“Kardionet”) in Turkey. Fantom procedures were successfully conducted at all three centers with excellent acute patient outcomes. The physicians implanting Fantom provided the following feedback:

Prof. Bilal Boztosun recounted his experience saying, “During the implant procedure I was impressed with how easy Fantom was able to be delivered to the target location in comparison to first generation bioresorbable scaffolds. The x-ray visibility enabled me to visualize Fantom and accurately place the device with ease.”

Prof. Ömer Göktekin stated, “In Turkey, we strive to offer our patients the most advanced therapies. Bioresorbable scaffolds like Fantom have the potential to improve long-term outcomes compared with metal drug-eluting stents and are an important treatment option for my patients. During the implant procedure in a highly complex case, Fantom’s x-ray visibility enabled me to place two Fantom scaffolds edge-to-edge in order to completely cover the diseased arterial segment”.

Prof. Ismail Ates, shared, “Fantom is different from first generation bioresorbable scaffolds due to its thinner strut profile and x-ray visibility provided by the Tyrocore polymer, and I was able to see the benefits during the procedure. Bioresorbable scaffolds have the potential to reduce long-term complications compared to metallic drug eluting stents and represent the future of PCI therapy for Turkish patients.”

Fantom is a second-generation bioresorbable scaffold made from Tyrocore, REVA’s proprietary bioresorbable polymer, which is different from the polylactic acid polymer used to construct first generation scaffolds such as Absorb. The use of Tyrocore allows Fantom to offer differentiated features compared to first generation scaffolds including thinner profiles, improved ease-of-use, and full x-ray visibility. “Our experience with Kardionet so far indicates that we chose the right partner for commercialization in Turkey,” said Reggie Groves, CEO, REVA. “We have hit all of our second quarter milestones including local registration approval, training, product shipments, and now the first implants. The successful approach we have established in Turkey will be our model for several additional commercial distribution partnerships we plan to initiate in the next six to twelve months.”


Disclaimer

The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkine.com.au and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

w

Connecting to %s